Published online before print January 16, 2003, doi: 10.1161/01.STR.0000053032.14223.81
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2003;34:482.)
© 2003 American Heart Association, Inc.
Original Contributions |
Tolerability of NXY-059 at Higher Target Concentrations in Patients With Acute Stroke
From the University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, UK (K.R.L.); Stroke Research Team, Queen Elizabeth Hospital, Gateshead, UK (D.B.); Wolfson Unit of Clinical Pharmacology, Department of Pharmacological Sciences, University of Newcastle-Upon-Tyne, Newcastle, UK (G.A.F.); Department of Neurology, University of Heidelberg, Heidelberg, Germany (W.H.); Department of Neurology, Huddinge University Hospital, Huddinge, Sweden (V.K.); Department of Medicine for the Elderly, University Hospital Aintree, Lower Lane, Liverpool, UK (A.K.S.); and Astra Zeneca, R&D, Södertälje, Sweden (T.O.).
Correspondence to Professor K.R. Lees, University Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT UK. E-mail k.r.lees{at}clinmed.gla.ac.uk
Background and Purpose— NXY-059 is a nitrone-based free radical–trapping agent in development for acute stroke. In patients with acute stroke, NXY-059 is well tolerated at concentrations known to be associated with neuroprotection in animal models of transient cerebral ischemia; however, higher target concentrations appear necessary on the basis of animal models of permanent ischemia.
Methods— This was a randomized, double-blind, placebo-controlled, parallel-group, dose-escalation, multicenter study that evaluated safety, tolerability, and plasma concentrations of 2 NXY-059 dosing regimens within 24 hours of acute stroke. NXY-059 was administered as either 915 mg over 1 hour followed by 420 mg/h for 71 hours or 1820 mg for 1 hour followed by 844 mg/h for 71 hours; plasma concentrations were monitored. Neurological and functional outcomes were recorded for up to 30 days.
Results— One hundred thirty-five patients were recruited, of whom 134 received study treatment and completed assessments (844 mg/h, n=39; 420 mg/h, n=48; placebo, n=47). Mean age was 69 years (range, 34 to 92 years), and baseline National Institutes of Health Stroke Scale score was 8.5 (SD, 6.6). Serious adverse events occurred in 3, 17, and 13 patients, respectively, with deaths in 0, 4, and 3 patients and treatment discontinuations because of adverse events in 0, 1, and 3 patients. Good outcome, defined by modified Rankin Scale score of 0 or 1, was seen in 53%, 29% and 40%, respectively. No safety concern was identified in analysis of body temperature, blood pressure, or other laboratory parameters. The unbound plasma concentration at steady state was 260±79 µmol/L, exceeding the target of 200 µmol/L in the high-dose group.
Conclusions— NXY-059 was well tolerated in patients with an acute stroke at and above concentrations shown to be neuroprotective in an animal model when initiated 4 hours after onset of permanent focal ischemia.
Key Words: free radicals • neuroprotection • NXY-059 • safety
This article has been cited by other articles:
 |
|
 |
|
  J. Gabrielsson and A. R. Green Quantitative Pharmacology or Pharmacokinetic Pharmacodynamic Integration Should Be a Vital Component in Integrative Pharmacology J. Pharmacol. Exp. Ther., December 1, 2009; 331(3): 767 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. Wasiewski To Phase 3 or Not to Phase 3? Stroke, May 1, 2009; 40(5): 1553 - 1554. [Full Text] [PDF]
|
|
|
|
 |
|
 M Akhtar, K. Pillai, and D Vohora Effect of thioperamide on oxidative stress markers in middle cerebral artery occlusion model of focal cerebral ischemia in rats Human and Experimental Toxicology, October 1, 2008; 27(10): 761 - 767. [Abstract] [PDF]
|
|
|
|
|
|
J. A. Zivin Clinical Trials of Neuroprotective Therapies Stroke, February 1, 2007; 38(2): 791 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Lees, A. Davalos, S. M. Davis, H.-C. Diener, J. Grotta, P. Lyden, A. Shuaib, T. Ashwood, H.-G. Hardemark, W. Wasiewski, et al. Additional Outcomes and Subgroup Analyses of NXY-059 for Acute Ischemic Stroke in the SAINT I Trial Stroke, December 1, 2006; 37(12): 2970 - 2978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J Fong and D. H Rhoney NXY-059: Review of Neuroprotective Potential for Acute Stroke Ann. Pharmacother., March 1, 2006; 40(3): 461 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Lees, J. A. Zivin, T. Ashwood, A. Davalos, S. M. Davis, H.-C. Diener, J. Grotta, P. Lyden, A. Shuaib, H.-G. Hardemark, et al. NXY-059 for Acute Ischemic Stroke N. Engl. J. Med., February 9, 2006; 354(6): 588 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Ley, A. Vigdorchik, L. Belayev, W. Zhao, R. Busto, L. Khoutorova, D. A. Becker, and M. D. Ginsberg Stilbazulenyl Nitrone, a Second-Generation Azulenyl Nitrone Antioxidant, Confers Enduring Neuroprotection in Experimental Focal Cerebral Ischemia in the Rat: Neurobehavior, Histopathology, and Pharmacokinetics J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1090 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Warner, H. Sheng, and I. Batinic-Haberle Oxidants, antioxidants and the ischemic brain J. Exp. Biol., August 15, 2004; 207(18): 3221 - 3231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W.B. Marshall, R. M. Cummings, L. J. Bowes, R. M. Ridley, and A. R. Green Functional and Histological Evidence for the Protective Effect of NXY-059 in a Primate Model of Stroke When Given 4 Hours After Occlusion Stroke, September 1, 2003; 34(9): 2228 - 2233. [Abstract] [Full Text] [PDF]
|
|